One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Yelena Yuriy Janjigian, Kohei Shitara, Markus Hermann Moehler, Marcelo Garrido S, Pamela Salman, Lin Shen, Lucjan Stanislaw Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli and 19 more
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Janjigian, Y. Y., Shitara, K., Moehler, M. H., S, M. G., Salman, P., Shen, L., Wyrwicz, L. S., Yamaguchi, K., Skoczylas, T., Bragagnoli, A. S. C., Liu, T., Schenker, M., Yanez, P. E., Tehfe, M. A., Kowalyszyn, R. D., Karamouzis, M. V., Bruges, R. E., Zander, T., Pazo-Cid, R., … Ajani, J. A. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet, 398(10294), 27–40. https://doi.org/10.1016/s0140-6736(21)00797-2
Janjigian, Yelena Yuriy, et al. "First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial." The Lancet, vol. 398, no. 10294, 2021, pp. 27–40, https://doi.org/10.1016/s0140-6736(21)00797-2.
Janjigian, Yelena Yuriy, Kohei Shitara, Markus Hermann Moehler, Marcelo Garrido S, Pamela Salman, Lin Shen, Lucjan Stanislaw Wyrwicz, et al. "First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial." The Lancet 398, no. 10294 (2021): 27–40. https://doi.org/10.1016/s0140-6736(21)00797-2.
Janjigian Y. Y., Shitara K., Moehler M. H. [и др.] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial // The Lancet. — 2021. — Vol. 398, № 10294. — P. 27–40. — URL: https://doi.org/10.1016/s0140-6736(21)00797-2
@article{janjigian2021firstline,
title = {{First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial}},
author = {Yelena Yuriy Janjigian and Kohei Shitara and Markus Hermann Moehler and Marcelo Garrido S and Pamela Salman and Lin Shen and Lucjan Stanislaw Wyrwicz and Kensei Yamaguchi and Tomasz Skoczylas and Arinilda Silva Campos Bragagnoli and Tianshu Liu and Michael Schenker and Patricio Eduardo Yanez and Mustapha Ali Tehfe and Rubén Dario Kowalyszyn and Michalis V. Karamouzis and Ricardo Elias Bruges and Thomas Zander and Roberto Pazo-Cid and Erika Hitre and Kynan Feeney and James M. Cleary and Valerie Poulart and Dana Cullen and Ming Lei and Hong Xiao and Kaoru Kondo and Mingshun Li and Jaffer A. Ajani},
journal = {The Lancet},
year = {2021},
volume = {398},
number = {10294},
pages = {27--40},
doi = {10.1016/s0140-6736(21)00797-2},
url = {https://doi.org/10.1016/s0140-6736(21)00797-2}
}TY - JOUR AU - Janjigian, Yelena Yuriy AU - Shitara, Kohei AU - Moehler, Markus Hermann AU - S, Marcelo Garrido AU - Salman, Pamela AU - Shen, Lin AU - Wyrwicz, Lucjan Stanislaw AU - Yamaguchi, Kensei AU - Skoczylas, Tomasz AU - Bragagnoli, Arinilda Silva Campos AU - Liu, Tianshu AU - Schenker, Michael AU - Yanez, Patricio Eduardo AU - Tehfe, Mustapha Ali AU - Kowalyszyn, Rubén Dario AU - Karamouzis, Michalis V. AU - Bruges, Ricardo Elias AU - Zander, Thomas AU - Pazo-Cid, Roberto AU - Hitre, Erika AU - Feeney, Kynan AU - Cleary, James M. AU - Poulart, Valerie AU - Cullen, Dana AU - Lei, Ming AU - Xiao, Hong AU - Kondo, Kaoru AU - Li, Mingshun AU - Ajani, Jaffer A. TI - First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial JO - The Lancet VL - 398 IS - 10294 SP - 27 EP - 40 PY - 2021 DA - 2021/06/05 DO - 10.1016/s0140-6736(21)00797-2 UR - https://doi.org/10.1016/s0140-6736(21)00797-2 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.